Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty acid synthesis (FAS) II pathway. Affinium’s FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway and are not subject to resistance selection pressures caused by the use of existing broad spectrum antibiotics.

Contact Details: 1243 Islington Ave., Suite 600 Toronto Ontario M8X 1Y9 Canada Tel: 416-645-6613 Fax: 416-646-1553 Email: oroberts@afnm.com WWW: www.afnm.com/

Loading...

Recent Publications by Affinium Pharmaceuticals:
Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI). Spiropiperidine naphthyridinone inhibitors of Staphylococcus aureus and...	18th August, 2009	Affinium Pharmaceuticals Inc. 1243 Islington Ave., Suite 600, Toronto,	Bioorg Med Chem Lett. 2009 Sep 15;19(18):5355-8. Epub 2009 Aug 6. DOI Direct Link
2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. In the search for new antibacterial agents, the enzyme FabI has been...	18th August, 2009	Affinium Pharmaceuticals Inc., 1243 Islington Avenue, Suite 600, Toronto,	Bioorg Med Chem Lett. 2009 Sep 15;19(18):5359-62. Epub 2009 Jul 23. DOI Direct Link
Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system. We have developed a high-throughput system for generating baculoviruses...	9th February, 2006	Affinium Pharmaceuticals, Toronto, Canada.	J Proteome Res. 2005 Nov-Dec;4(6):2225-35. DOI Direct Link
The structure of (3R)-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Pseudomonas aeruginosa. Type II fatty acid biosynthesis systems are essential for membrane...	3rd February, 2005	Affinium Pharmaceuticals, Toronto, Ontario M5J 1V6, Canada.	J Biol Chem. 2004 Dec 10;279(50):52593-602. Epub 2004 Sep 14. DOI Direct Link
Reduced triclosan susceptibility in methicillin-resistant Staphylococcus epidermidis. Triclosan MIC determination showed that recent Staphylococcus aureus...	25th May, 2004	Affinium Pharmaceuticals, Inc., Toronto, Ontario M5J 1V6, Canada.	Antimicrob Agents Chemother. 2004 Apr;48(4):1397-9.
→View more Affinium Pharmaceuticals research publications.

Press Releases on Affinium Pharmaceuticals:
European Biotechnology Crossroads presents international conference	1st January, 1970	Ala	European Biotechnology Crossroads presents international conference programme 7th European Biotech Crossroads presents international

BioNews Results for Affinium Pharmaceuticals:
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer	FinanzNachrichten.de:  Nov 16 2009 12:34AM Matching: pharmaceuticals
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu	Washington Business Journal:  Nov 16 2009 1:25AM Matching: pharmaceuticals
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu	St Louis Business Journal:  Nov 16 2009 12:45AM Matching: pharmaceuticals
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu	San Jose Business Journal:  Nov 16 2009 12:35AM Matching: pharmaceuticals
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu	Reuters:  Nov 16 2009 12:43AM Matching: pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Affinium Pharmaceuticals news.

Affinium Pharmaceuticals Patents:
US Patent No.	Title
7601526	Purified FabI polypeptides from Fransicella tularensis
6951729	High throughput screening method for biological agents affecting fatty acid biosynthesis
6846819	Fab I inhibitors
6821746	Methods of screening for FabK antagonists and agonists
6797523	Methods for systematic identification of protein--protein interactions
→View more Affinium Pharmaceuticals patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 2074 times since April 2007, the link to the organisation's website has been followed 280 times

Recent Search Terms used to find this page: affinium pharmaceuticals 2009 | Affinium Pharmaceuticals email | affinium pharmaceuticals canada | affinium pharmaceuticals 2009 | affinium pharmaceutical | affinium pharmaceuticals | Affinium Pharmaceuticals Inc. canada | affinium pharmaceutical 100 university | Affinium Pharmaceutical AFN-1252 | affinium pharmaceuticals inc.canada | .

Search for more companies in Toronto

Search for more companies in Ontario

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Affinium Pharmaceuticals